The differences between PFSs and MDVs (per 1000 doses) is 324.21. MDV: Multidose vial; NA: Not available; PFS: Prefilled syringe. Prefilled syringes (PFSs) have gained market share in the USA ...

The U.S. Centers for Disease Control and Prevention decided, opens new tab to hold off recommending the use of the vaccine, Arexvy, in adults under 60, despite the Food and Drug Administration ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 ...

With cold and flu season around the corner, Doctors recommend receiving the RSV vaccine ahead of the holidays.

The U.S. Centers for Disease Control and Prevention decided to hold off recommending the use of the vaccine, Arexvy, in adults under 60, despite the Food and Drug Administration approving it for that ...

Three FDA approved RSV vaccines are available for adults- GSK’s Arexvy, Pfizer’s Abrysvo and Moderna’s mResvia. The best way to prevent the spread of RSV is to watch hands regularly and ...

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) in a broader population of adults at increased for RSV disease. Arexvy ...